Moderna, Inc.
28.6.2024 13:03:23 CEST | ACCESS Newswire | Press release
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Following the CHMP's positive opinion, the European Commission will adopt a decision on the authorization of mRESVIA.
"The positive opinion from the EMA CHMP for mRESVIA highlights the innovation and adaptability of our mRNA platform," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors. With mRESVIA, we continue to make significant strides in addressing global public health challenges posed by respiratory diseases, and we look forward to the decision on an EU-wide marketing authorization from the European Commission."
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. It causes a particularly high burden of disease in infants and older adults. In the European Union, RSV is estimated to cause approximately 160,000 hospital admissions in adults each year, with 92% of these admissions occurring in adults aged 65 and over. [1]
The CHMP positive opinion for mRESVIA is based on positive data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults ages 60 years or older in 22 countries. The primary analysis with 3.7 months of median follow-up found a vaccine efficacy (VE) against RSV lower respiratory tract disease (LRTD) of 83.7% (95.88% CI 66.0%, 92.2%), with these results published in The New England Journal of Medicine. In a supplementary analysis with 8.6 months of median follow-up, mRNA-1345 maintained durable efficacy, with sustained VE of 63.3% (95% CI: 48.7%, 73.7%) against RSV-LRTD, including two or more symptoms. VE was 74.6% (95% CI, 50.7, 86.9) against RSV-LRTD with ≥2 symptoms, including shortness of breath, and VE was 63.0% (95% CI, 37.3%, 78.2%) against RSV LRTD including three or more symptoms. The stringent statistical criterion of the study, a lower bound on the 95% CI of >20%, continued to be met for both endpoints. The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia, and arthralgia.
In May 2024, the U.S. Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marked Moderna's second approved mRNA product. Moderna has filed for mRNA-1345 marketing authorization applications in multiple markets worldwide.
About mRESVIA ® (Respiratory Syncytial Virus Vaccine)
mRESVIA ® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential authorization by the European Commission of Moderna's RSV vaccine mRESVIA; the vaccine efficacy and safety of mRNA-1345; the potential for mRESVIA to reduce disease burden from RSV; and Moderna's pending marketing authorization applications for mRNA-1345. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
[1] Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Bøås H, van Boven M, Wang X, Lehtonen T, Bangert M, Campbell H, Paget J; Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators. Estimation of the Number of Respiratory Syncytial Virus-Associated Hospitalizations in Adults in the European Union. J Infect Dis. 2023 Nov 28;228(11):1539-1548. doi: 10.1093/infdis/jiad189. PMID: 37246742; PMCID: PMC10681866.
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
APEX FTE Expo 2026 Unites Aviation Leaders in Singapore and Honors Passenger Experience Excellence20.11.2026 19:22:00 CET | Press release
SINGAPORE, SG / ACCESS Newswire / November 20, 2026 / APEX FTE EXPO 2026 brought together nearly 2,000 registered airline, airport, and industry leaders at Marina Bay Sands Expo & Convention Centre, bringing APEX's flagship show back to Singapore for the first time in a decade as the largest end-to-end passenger experience and innovation expo, spanning every stage of the passenger journey. Hosted by the Airline Passenger Experience Association (APEX), Future Travel Experience (FTE), and the International Flight Services Association (IFSA), the EXPO united over 300 airline representatives from more than 60 airlines worldwide, airport operators, and more than 100 exhibitors under one roof, building on 15 years of APEX FTE's Asia event. The two days culminated in the APEX Awards Ceremony, where the industry honored the leaders, airlines, and innovators whose work passengers feel long after they land. Across two days of airline chief executive keynotes, exclusive announcements, live culina
Tosca's 2026 Sustainability Report Makes the Case for Packaging as Critical Supply Chain Infrastructure20.11.2026 08:00:00 CET | Press release
BRUSSELS, BE / ACCESS Newswire / November 20, 2026 / Tosca, a global leader in reusable packaging and pooling solutions, has released its 2026 Sustainability Report, calling for a shift in how businesses evaluate transport packaging: from a purchased commodity to a strategic component of supply chain infrastructure. As food supply chains become more automated and face mounting cost and regulatory pressures, packaging decisions increasingly influence operational performance. The report examines how reusable packaging can reduce food loss, labor requirements and transportation inefficiencies while documenting Tosca's progress toward its global sustainability goals. "Companies invest significant resources in optimizing equipment, labor and transportation, yet packaging is still too often evaluated primarily on unit price," said Eric Frank, CEO of Tosca. "That approach overlooks its role in keeping automated lines running, protecting products and moving goods efficiently. Packaging is an o
Global Scams Remain Widespread: Nearly Two in Three Adults Worldwide Report Scam Encounters, 9% Lost Money19.11.2026 18:01:00 CET | Press release
THE HAGUE, NL / ACCESS Newswire / November 19, 2026 / The Global Anti-Scam Alliance (GASA), in collaboration with Outseer, today released the Global State of Scams 2026 report. Based on a survey of 58,900 adults across 42 markets, the report examines how often people encounter scams, how they respond, and the financial and emotional impact on those affected. In the past 12 months, 64% of adults worldwide encountered a scam and 9% lost money. Shopping, investment, and unexpected money scams were among the types people most often interacted with. In Africa, 21% of adults lost money to a scam, more than double the global rate. The research also highlights the emotional toll of scams. Among people who lost money, 69% reported a significant or moderate impact on their mental wellbeing, 20% reported increased tension at home, and 16% said they could not pay for essentials such as rent or groceries. Among those who did not report the scam to an organization, the most common reason was uncerta
After 20 Years of Modernizing Other Companies' Software, Polcode Turns the Lens on Itself19.11.2026 15:00:00 CET | Press release
WARSAW, PL / ACCESS Newswire / November 19, 2026 / Polcode, a software development company that has helped businesses across North America and Europe modernize their technology since 2006, launched its new website at polcode.com this week. Timed to the company's 20th anniversary, the launch is more than a redesign. It applies the same modernization approach Polcode brings to client systems every day to its own brand. For 20 years, Polcode has been the team businesses call when software stops keeping up with the business: aging platforms, tangled integrations, and tools nobody dares touch. So when it came time to rebuild its own website, the question was fair. Would a company that modernizes for others hold itself to the same standard? The new site is Polcode's answer, serving as both a showcase of what the company does and an example of it. We spend a lot of time helping businesses move beyond systems that no longer reflect where they're headed. At some point, we had to ask ourselves t
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval19.11.2026 13:45:00 CET | Press release
CALGARY, AB / ACCESS Newswire / November 19, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it has completed registration under the Compliance Instrument Tracking System Service (CITSS), enabling the Company to participate directly in California's regulated compliance carbon market. This milestone elevates Karbon-X's North American trading infrastructure, enabling the Company to directly source, hold, and transact compliance allowances and eligible offset credits, positioning the Company to capture trading margins and recurring commercial opportunities from California's ongoing compliance demand. Unlike voluntary carbon markets, California's Cap-and-Invest Program is backed by state regulation requiring covered entities to surrender eligible compliance instruments against their emissions obligations, creating recurring regulatory demand for allowances and eligible offset credits. California's pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
